MR
MRK
Year ended Dec 31, 2023 · FY2025 10-K

Merck & (MRK) 10-K Summary — Year Ended Dec 31, 2023

The filing reports Merck's annual results for the most recent fiscal year. Revenue increased from the prior year, net income was positive, and operating cash flow remained strong.

Key takeaway

Year ended Dec 31, 2023 · FY2025 10-K

The filing reports Merck's annual results for the most recent fiscal year. Revenue increased from the prior year, net income was positive, and operating cash flow remained strong.

Financial snapshot

Selected annual figures reported with the filing, shown separately from the narrative summary.

Annual revenue

$60.1B

Revenue reported for the fiscal year.

Operating income

n/a

Income from operations reported for the year.

Net income

$365M

Net income reported for the year.

Operating cash flow

$13B

Cash generated by operating activities.

Annual revenue trend

Reported annual revenue and its change from the preceding fiscal year.

Period endedRevenueYear-over-year change
Dec 31, 2021$48.7Bn/a
Dec 31, 2022$59.3B+21.7%
Dec 31, 2023$60.1B+1.4%

Business overview

The supplied filing sections do not include a description of the company's business. Only item headings are listed without any explanatory text.

Financial performance

Revenue showed strong growth in the earlier period and continued to rise at a slower pace in the most recent period. Net income and operating cash flow were reported as positive.

Material risks

No specific risk factors are described in the supplied filing context. Only a list of risk factor headings is provided, with no further detail.

Liquidity and capital

The liquidity and capital resources discussion highlights a strong financial profile that supports research and development, acquisitions, and shareholder returns. The decline in working capital was driven by business development activities, partly offset by operating performance and debt issuance, while operating cash flow was reduced by collaboration payments and a settlement.

What to watch

Investors should monitor the impact of large collaboration payments, such as the one with Daiichi Sankyo, on future operating cash flow.

Merck & (MRK) 10-K Summary — Year Ended Dec 31, 2023